Former President Joe Biden’s prostate cancer has progressed since his diagnosis in May 2025, according to his son Hunter Biden in a recent BBC interview. Hunter disclosed that the cancer has metastasized to his father’s bones, causing significant pain and debilitation. He expressed concern over his father’s health, stating, “I wish he would complain more, because it’s not good.” Biden, now 83, initially revealed that a small nodule was found during a routine exam. His office indicated that while the cancer is aggressive, it is hormone-sensitive, allowing for management options. Biden has undergone hormone therapy and radiation treatment, completing a radiation course in October 2025. Common treatment methods for prostate cancer include chemotherapy and immunotherapy, with new screening methods being researched.
Why It Matters
Prostate cancer is the second-most common cancer among men, with rising incidence rates; the American Cancer Society reports a 3% annual increase from 2014 to 2021. In 2026, an estimated 333,830 new cases will be diagnosed in the U.S., with about 36,320 men expected to die from the disease. The average age at diagnosis is 67, with older men at higher risk. Early detection through screening can significantly improve survival rates, with localized prostate cancers having a five-year survival rate of at least 99%. Understanding Biden’s condition highlights the broader public health issue surrounding prostate cancer and the importance of ongoing research and treatment options.
Want More Context? 🔎
